allogeneic stem-cell transplantation engineered donor lymphocytes after - Antitumor effects of HSV-TK

doi:10.1182/blood-2006-05-023416Prepublished online February 27, 2007;2007 109: 4698-4707€€€€Traversari and Claudio BordignonSalomoni, Claudia Benati, Maurilio Ponzoni, Luciano Callegaro, Paolo Corradini, Marco Bregni, CatiaAlessandra Pescarollo, Attilio Bondanza, Jacopo Peccatori, Silvano Rossini, Zulma Magnani, Monica Fabio Ciceri, Chiara Bonini, Sarah Marktel, Elisabetta Zappone, Paolo Servida, Massimo Bernardi,€

[1]  C. Bordignon,et al.  The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. , 2007, Blood.

[2]  J. Serody,et al.  Leukocyte migration and graft-versus-host disease. , 2005, Blood.

[3]  C. Bordignon,et al.  Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Sorror,et al.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Mackinnon,et al.  Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. , 2004, Blood.

[6]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Romero,et al.  Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells. , 2003, Blood.

[8]  A. Hagenbeek,et al.  Safety of retroviral gene marking with a truncated NGF receptor , 2003, Nature Medicine.

[9]  S. Riddell,et al.  Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. , 2003, Blood.

[10]  E. Warren,et al.  Minor histocompatibility antigens-targets of graft versus leukemia responses , 2002, International journal of hematology.

[11]  J. Melo,et al.  Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. , 2002, Blood.

[12]  F. Appelbaum,et al.  Haematopoietic cell transplantation as immunotherapy , 2001, Nature.

[13]  Craig W. Reynolds,et al.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. , 2001, Blood.

[14]  G. Morgan,et al.  In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. , 2000, Blood.

[15]  R. Collins,et al.  Donor leukocyte infusions in acute lymphocytic leukemia , 2000, Bone Marrow Transplantation.

[16]  S. Nantel,et al.  Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia , 2000, Bone Marrow Transplantation.

[17]  W. M. Smit,et al.  Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. , 1999, Blood.

[18]  M. Shlomchik,et al.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.

[19]  D. Klatzmann,et al.  Would suicide gene therapy solve the 'T-cell dilemma' of allogeneic bone marrow transplantation? , 1999, Immunology today.

[20]  P. Tiberghien.  "Suicide" gene for the control of graft-versus-host disease. , 1998, Current opinion in hematology.

[21]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[22]  C. Bordignon,et al.  Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. , 1998, Human gene therapy.

[23]  J. Cornelissen,et al.  Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. , 1997, Blood.

[24]  J. York,et al.  Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. , 1997, Blood.

[25]  D. Pardoll.  Taming the sinister side of BMT: Dr. Jekyll and Mr. Hyde , 1997, Nature Medicine.

[26]  S. Strober,et al.  Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. , 1997, Blood.

[27]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[28]  I. Wickelgren.  New Lead to Safer Marrow Transplants , 1997, Science.

[29]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[31]  H. Kantarjian,et al.  CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. , 1995, Blood.

[32]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[33]  S. Mackinnon,et al.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.

[34]  R. Giavazzi,et al.  Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. , 1995, Human gene therapy.

[35]  F. Aversa,et al.  Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. , 1994, Blood.

[36]  Craig W. Reynolds,et al.  Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? , 1994, Blood.

[37]  X. Breakefield,et al.  Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. , 1994, Human gene therapy.

[38]  Z. Bebők,et al.  Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. , 1994, Gene therapy.

[39]  M. Ladanyi,et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.

[40]  C. Richards,et al.  In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. , 1993, Cancer research.

[41]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[42]  W. Wilmanns,et al.  Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients , 1990 .

[43]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[44]  J. Melo,et al.  Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. , 2001, Blood.

[45]  C. Craddock,et al.  Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. , 2000, Blood.

[46]  R Pabst,et al.  HIV-induced decline in blood CD4/CD8 ratios: viral killing or altered lymphocyte trafficking? , 1998, Immunology today.